PMC:101390 / 24155-25315 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/101390","sourcedb":"PMC","sourceid":"101390","source_url":"https://www.ncbi.nlm.nih.gov/pmc/101390","text":"Conclusions\nFrom a technological point of view it is simpler to handle an extracellular enzyme than a cell-linked one. The amount of extracellular COX of the non-pathogenic strain R. erythropolis ATCC 25544 obtained in a 1.5 1 batch fermentation represents a 36% of the activity (130 out of 360 U/ml) when measured directly from the broth, but after the 6% Triton X-114 treatment and phase separation it represents a 65% of the total activity (442 out of 672 U/ml). In addition, active COX becomes 11.6 times purer and 20.3 times more concentrated. These results may make attractive and cost-effective the use of this bacterial strain and the Triton X-114 phase separation in a 6% w/v for the industrial production of COX used in serum and food cholesterol analysis. The purification step based on Triton X-114 phase separation should be followed by further steps, such as ion-exchange chromatography, which can combine non-ionic detergent removal and protein purification in one step, in order to obtain a preparation of COX suitable for analytical applications [16].\nInvestigations to improve the percentage of extracellular COX are currently under progress.","divisions":[{"label":"title","span":{"begin":0,"end":11}},{"label":"p","span":{"begin":12,"end":1068}}],"tracks":[{"project":"2_test","denotations":[{"id":"11914155-1368208-8561983","span":{"begin":1064,"end":1066},"obj":"1368208"}],"attributes":[{"subj":"11914155-1368208-8561983","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#d893ec","default":true}]}]}}